B&L PureVision
This article was originally published in The Gray Sheet
Executive Summary
Washington D.C. federal appeals court declines to stay injunction against sales of the Bausch & Lomb extended-wear contact lens after a lower court's patent infringement ruling. The appeals process could take six-to-18 months, B&L says. As a result, the firm will move its PureVision manufacturing facilities to Ireland to ensure a continued supply to customers in Europe and Asia. A Delaware federal court found on June 26 that the device infringes a patent owned by CIBA Vision unit Wesley Jessen, blocking U.S. sales and production (11"The Gray Sheet" July 29, 2002, p. 17). B&L expects the decision will cost it $10 mil. in sales and $0.12-0.15 in earnings per share for the second half of 2002...